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mors usually have vascularized septa and parietal nodules. In 
summary, CEUS is effective for differentiating solid pancre-
atic tumors in most cases. CEUS is safe and cost effective and 
can better discriminate solid from cystic pancreatic lesions, 
thereby directing further imaging modalities. 
 Copyright © 2011 S. Karger AG, Basel and IAP 
 Introduction 
 Pancreatic carcinoma is an aggressive and devastating 
disease. It is characterized by invasiveness, rapid progres-
sion and profound resistance to treatment. Only 10–20% 
of patients with pancreatic cancer are diagnosed with tu-
mors suitable for surgical resection, the only cure. Imag-
ing of pancreatic tumors employs various techniques 
such as B-mode ultrasound (US), color Doppler sonogra-
phy, endoscopic US, computed tomography (CT) and 
magnetic resonance imaging (MRI). Unfortunately, in up 
to 30% of patients determined to have a resectable tumor 
by preoperative imaging the lesion is deemed unresect-
able during surgery  [1, 2] .
 US is usually the first approach to investigation due to 
its relatively low costs, noninvasiveness, and general 
availability. B-mode US allows for the identification of 
focal lesions, even small ones of   1 cm in diameter, which 
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 Abstract 
 Since its introduction, contrast-enhanced ultrasonography 
(CEUS) has significantly extended the value of ultrasonogra-
phy (US). CEUS can be used to more accurately determine 
pancreatic lesions compared to conventional US or to char-
acterize lesions already detectable by US. Thus, CEUS can aid 
in the differential diagnosis of pancreatic tumors. Using US 
contrast media, it is possible to visually detect microvessels 
in the majority of pancreatic ductal adenocarcinomas. Thus, 
the use of quantitatively evaluated transabdominal CEUS can 
help in the differentiation of patients with mass-forming pan-
creatitis from patients with pancreatic adenocarcinomas. In 
neuroendocrine pancreatic tumors, different enhancement 
patterns can be observed in relation to the tumor mass: larg-
er ones show a rapid early enhancement sometimes com-
bined with necrotic central structures, and smaller ones dis-
close a capillary-blush enhancement. Pseudocysts, the most 
widespread cystic lesions of the pancreas, are not vascular-
ized. They do not show any signal in CEUS and remain en-
tirely anechoic in all phases, while true cystic pancreatic tu-
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are usually hypoechoic or cystic. Nevertheless, among 
these hypoechoic lesions, B-mode US is unable to dis-
criminate adenocarcinomas from islet cell tumors or 
even rarer diseases, such as microcystic adenomas or fo-
cal pancreatitis. The advantages of CT and MRI include 
the ability to assess more lesion types during different 
dynamic phases.
 Since its introduction in 1995, contrast-enhanced US 
(CEUS) has offered a wide array of diagnostic possibilities 
and has significantly extended the value of US. It has al-
ready proven to be a competent tool for evaluating the 
liver. However, other organs, particularly the pancreas, 
can be examined during continuous US imaging  [3] . 
CEUS can be used to improve the visualization of pancre-
atic lesions compared to conventional US or to character-
ize lesions already detectable by US. CEUS provides high 
contrast and spatial resolution. Utilizing microbubbles, 
which represent an inherent contrast medium in the 
blood pool, perfusion of a tissue can be visualized with-
out motion artifacts. Also, tumor enhancements can be 
seen more clearly by deleting background tissue signals 
and permitting dynamic observations in the same plane 
 [3–5] . Together, these abilities make CEUS a sensitive im-
aging technique for estimating the vascularity of pancre-
atic lesions. Neoangiogenesis and residual tumors can be 
precisely studied to assess treatment response because 
CEUS can visualize tumor vascularization  [4–9] . In ad-
dition, it has been reported that CEUS imaging is supe-
rior to helical CT regarding the identification of pancre-
atic tumor vascularization  [7] .
 Using US contrast media, it is possible to visually de-
tect microvessels in the majority of pancreatic ductal ad-
enocarcinomas (PDACs). A previous study found a sen-
sitivity of 95% for the detection of carcinomas  [10] . How-
ever, using this technology, the subjective assessment of 
the degree of vascularization still remains problematic 
because the examiner must make a judgment based on a 
personal impression of brightness and contrast compared 
to the surrounding tissue. In addition, interindividual 
comparisons are not possible using this method. How-
ever, software algorithms can be used to quantify chang-
es in contrast intensity. Thus, objective information can 
be obtained for the entire contrast-enhanced examina-
tion. In one of our recently published studies  [11] , the use 
of quantitatively evaluated transabdominal CEUS en-
abled the differentiation of patients with mass-forming 
pancreatitis from patients with pancreatic adenocarcino-
mas. Thus, CEUS can notably improve the accuracy of 
US, leading to a better recognition and description of 
pancreatic lesions  [4–9] . Additionally,  endoscopic CEUS 
has also been described as a useful tool for the differential 
diagnosis of pancreatic lesions in patients with chronic 
pancreatitis  [12–14] .
 Compared to CT and MRI, the CEUS technique is 
simple and inexpensive. It is noninvasive and can be ac-
complished in an outpatient setting. It can also be per-
formed on patients with renal failure or patients allergic 
to iodine contrast agents  [3, 15] . Contrary to the contrast 
agents used in CT or MRI, US contrast agents are gener-
ally well tolerated. In a study of  1 23,000 applications of 
US contrast agents, only 29 cases of adverse events were 
reported, and these were mostly minor complaints such 
as rash or pruritus. Of all the adverse events, only 2 ana-
phylactic reactions were graded as serious, and both re-
solved completely without permanent damage  [16] . Thus, 
CEUS is generally contraindicated in patients who may 
develop fatal anaphylactic reactions, e.g. in patients with 
a history of unstable cardiac conditions.
 At present, the application of CEUS is not part of the 
regular diagnostic routine applied for pancreatic cancer. 
It may be a tool for evaluating pathologic changes in pan-
creatic cancer and may provide useful information for 
staging before treatment  [17] .
 Technical Background 
 Harmonic imaging with low acoustic pressure US is 
necessary for CEUS. Immediately after the injection of a 
second-generation contrast medium, the dynamic sur-
veillance of the contrast-enhanced phases begins (early 
arterial, arterial, pancreatic, and late). Sulfur hexafluo-
ride microbubbles can enter the microcirculation be-
cause of their low mean diameter of 2.5   m  [3] . The en-
hancement peaks between 15 and 20 s after the injection 
of the contrast medium. Pancreatic parenchymography is 
earlier and shorter than that of the liver due to the ab-
sence of portal venous blood supply. Afterwards, there is 
a progressive washout of contrast medium, with a loss of 
gland echogenicity  [3] . According to our previous re-
search, the mean arrival time in healthy volunteers is 14 s; 
the time to reach peak intensity was measured at 22 s, and 
the maximum intensity was 5.3 dB on average  [11] . These 
times can be considerably longer when measuring the 
contrast phase in pancreatic tumors or chronic pancre-
atitis. However, technical problems such as restricted im-
age resolution of deep regions and poor sonographic im-
aging of the pancreas due to overlying abdominal gas or 
fat can often impair the contrast-enhanced evaluation of 
the pancreas  [3, 5] .
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 Clinical Applications of CEUS for Pancreatic Tumors 
 Focal lesions that are hypoechoic on B-mode US can 
be classified by CEUS as hypo-, iso-, or hyperechoic ac-
cording to their enhancement compared to that of the 
adjacent parenchyma.
 Ductal Adenocarcinoma 
 Ductal adenocarcinoma is the type of pancreatic tu-
mor most frequently diagnosed. This pancreatic tumor 
usually shows a hypoenhanced/hypoechoic appearance 
in CEUS compared to the adjacent pancreatic tissue in all 
phases because of poor tumor vascularization  [17] . The 
margins and size of the lesion are better visible than with 
B-mode US ( fig. 1 ). The correlation with peripancreatic 
arterial and venous vessels can also be evaluated for local 
staging  [5, 7, 9, 18] . Tumors for which the size of the hy-
poechoic area is unaffected in CEUS have clear margins 
with no infiltration or inflammation. Tumors for which 
the size of the hypoechoic area is reduced in CEUS have 
indistinct margins with infiltration of cancerous cells 
and inflammation.
 The illustration of tumor margins by CEUS is more 
precise at low enhancements rather than high ones  [18] . 
High enhancement patterns of ductal adenocarcinomas 
by CEUS correlate with a low potential for determining 
resectability. In cases of well-differentiated carcinoma, 
the mass tends to be iso- or hypovascular compared to 
ROI 1 ROI 2
40.0
30.0
20.0
10.0
0
–0.1 4.9 9.9 14.9 19.9 24.9
Time (s)
In
te
ns
ity
 (d
B)
7.85, 8.14
b
 Fig. 1.  a PDAC in the pancreatic head. 
CEUS using 1.2 ml of SonoVue  in low-
mechanical index mode, 27 s after injec-
tion.  b Quantification of the contrast 
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the remaining parenchyma, and the margins of the tu-
mor are hard to evaluate. On the contrary, a confirmation 
of resectability can be precisely obtained by CEUS in the 
presence of hypovascular pancreatic tumors. In this
case, the border between the tumor and the normal 
neighboring pancreatic parenchyma is more clearly de-
fined. Therefore, the pattern of pancreatic adenocarci-
noma enhancement influences the image of tumor mar-
gins obtained by CEUS  [18] .
 Pancreatic carcinomas sometimes appear isoechoic. 
This pattern is a result of the moderate vascularization 
occurring in some histotypes (e.g. anaplastic and acinar-
cell carcinomas)  [19] . The isoechoic pattern is also fre-
quent in focal pancreatitis  [20] . Consequently, CEUS can-
not always accurately distinguish between adenocarcino-
ma and focal pancreatitis, similar to CT and MRI  [21] . 
However, supplemented with quantification software, 
data helpful for a differential diagnosis can be obtained 
( fig. 1 b). The mean arrival time for carcinoma lesions is 
reached on average 13 s later than in the normal pancre-
atic tissue of the same patient. On average, it takes 34 s 
longer to reach the measured peak in PDACs than in nor-
mal tissue, whereas the peak for mass-forming chronic 
pancreatitis is similar or only slightly longer than in nor-
mal tissue  [11] .
 Modern helical CT scans are generally accepted as the 
standard for the staging of PDACs. The improved ability 
of CEUS to demonstrate intratumoral vessels may be the 
reason why the common, well-vascularized aspects of 
PDAC are exposed by this imaging method. The use of 
CEUS may add significant information for the regional 
staging of pancreatic adenocarcinoma  [22] by confirming 
vascular infiltration or encasement by the neoplasm. Fur-
thermore, CEUS may enhance sensitivity and specificity 
in the identification and characterization of liver metas-
tases, especially in the detection of very small lesions  [23] . 
In practice, after studying a pancreatic lesion in the arte-
rial, pancreatic, and venous phases, liver metastases can 
be detected using the late hepatic contrast-enhanced 
phase  [5] .
 Endocrine Tumors 
 Endocrine islet cell tumors usually appear hyperecho-
ic/hypervascular in the arterial phase of imaging due to 
their rich vascularization  [24] . A differential diagnosis 
between endocrine tumors and ductal adenocarcinomas 
through imaging is of great value. Interestingly, different 
enhancement patterns can be observed in relation to the 
mass of tumors and tumor vessels. Voluminous endo-
crine tumors show a rapid and powerful enhancement in 
the early contrast-enhanced phases, with the exclusion of 
necrotic intralesional areas  [19, 24, 25] . In moderately 
sized neuroendocrine pancreatic tumors, a capillary-
blush enhancement can be seen in the early contrast-en-
hanced phase. Nonfunctioning neuroendocrine tumors 
may be hypovascularized, depending on the amount of 
stroma within the thick and hyalinized lesion. In some 
pancreatic neuroendocrine tumors, a hypodense image is 
visible on CT, whereas a clear enhancement is noticeable 
in CEUS  [25] . The ability of CEUS to demonstrate endo-
crine tumor vascularization is a consequence of the high 
resolving power combined with the blood pool circula-
tion of the microbubbles; therefore, the real-time dynam-
ic mode allows depicting vascularization in a way that CT 
and MRI do not permit. A similar CEUS pattern can also 
be observed in hypervascular metastases (from renal cell 
carcinomas and melanomas)  [19] .
 Cystic Tumors 
 CEUS improves the US differential diagnosis between 
pseudocysts and cystic tumors of the pancreas by reveal-
ing the vascularization of intralesional inclusions. Pseu-
docysts, the most widespread cystic lesion of the pancre-
as, are nonvascularized. They do not show any signal in 
CEUS and remain entirely anechoic in all phases, even if 
they appear inhomogeneous by US. In some cases, larger, 
peripancreatic vessels may be seen inside the pseudocyst. 
True cystic pancreatic tumors usually have vascularized 
septa and parietal nodules  [26] . A simple, imaging-based 
classification of pancreatic cystic lesions has been pro-
posed. Herein, there are four types: microcystic, unilocu-
lar, macrocystic, and cystic with a solid component  [27] .
 Serous cystadenomas have a benign biological behav-
ior in the great majority of cases. The most common type 
of serous cystadenoma is the microcystic type, macro-
scopically marked by multiple small cysts divided by thin 
septa. The margins are well defined, and a central scar 
may be present. B-mode US can be used to characterize 
serous microcystic adenomas if they demonstrate a typi-
cal honeycomb appearance  [27, 28] . In CEUS, intralesion-
al septal enhancement and the absence of papillary pro-
jections improve the recognition of microcystic features 
of the lesion and improve diagnostic accuracy. In the
case of small lesions that do not require surgical interven-
tion, CEUS results do not require further verification by 
CT and/or MRI.
 Less common oligocystic or macrocystic types of se-
rous cystadenomas present features that may be impos-
sible to distinguish from those of other pancreatic mac-
rocystic tumors  [4, 29] . Unilocular single cysts without 
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internal septa, solid components, and parietal or central 
calcifications on B-mode US can be classified as pseu-
docysts, oligocystic serous cystadenomas, mucinous 
cystic neoplasms (MCN), or intraductal papillary mu-
cinous neoplasms (IPMN)  [27] . Here, CEUS does not 
yield any additional diagnostic information. Specifical-
ly, CEUS imaging cannot show a communication with 
the pancreatic duct in the way that MR cholangiopan-
creatography or CT can do  [30] . Similarly, when two or 
more unilocular cysts are present, the differential diag-
nosis between pseudocysts and IPMNs  [27] cannot be 
made by CEUS, and the use of CT or MRI is required.
 Cysts with a solid component on B-mode US may be 
either unilocular or multilocular. True cystic tumors 
(MCN and IPMN) and solid tumors with a cystic region 
or cystic degeneration – primary or metastatic – are in-
cluded in this group. All tumors of this group are either 
malignant or have a high malignancy potential  [27] . 
Again, the use of CEUS cannot provide an important di-
agnostic contribution in these cases. 
 Macrocystic lesions include multilocular cysts with 
fewer and larger ( 1 2 cm) compartments than serous mi-
crocystic adenomas  [27] . This class includes MCN and 
IPMN. A thick wall, thick septae, and mural or septal cal-
cifications are the most important findings associated 
with malignancy  [27, 30] . In these cases, although CEUS 
permits better imaging of the wall and septae  [6] , it does 
not provide a significant diagnostic advantage over B-
mode US ( fig. 2 ).
 Discussion 
 The role of imaging methods in the differential diag-
nosis of pancreatic tumors has been reported as unsatis-
factory  [7, 31–37] . Consequently, a method with both high 
sensitivity and high specificity for tumor differentiation 
is needed due to the fact that tumor differentiation is es-
sential for appropriate therapy and a favorable prognosis. 
The vascular patterns of pancreatic tumors have been ex-
amined in patients with cystic and solid tumors using 
earlier second-harmonic imaging and other contrast-en-
hancing techniques with promising, but also conflicting, 
results  [6, 7, 10, 20, 29, 32, 38–48] .
 In most tumors, the degree of vascularity compared to 
the adjacent pancreatic parenchyma is helpful for tumor 
description. Tissue perfusion is altered by histological in-
terstitial changes caused by the underlying disease. Be-
cause tumors can only be nourished by diffusion up to a 
distance of 1–2 mm, tumor growth is highly dependent 
on the development of nutrient-supplying tumor vessels. 
These vessels are mostly capillaries between 5 and 8   m 
in diameter, and, histologically, they consist only of an 
endothelial layer without any surrounding smooth mus-
cle cells  [43] . Thus, the analysis of pathological perfusion 
patterns can aid in the differential diagnosis of lesions. 
However, none of the conventional imaging methods 
(unenhanced US, CT, MRI, angiography, or positron 
emission tomography) can sufficiently visualize micro-
vascularization of vessels with a diameter  ! 10   m and a 
flow  ! 1 mm/s  [49] because they are considerably smaller 
than the resolution of these imaging techniques, includ-
ing angiography. With CEUS, this barrier has been over-
come; although the capillary net is not anatomically 
 visible, microbubbles in the capillary perfusion can be 
observed as contrast enhancement  [50] and, thus, quan-
titatively measured.
 CEUS can distinguish between frequently hypovascu-
larized malignant ductal adenocarcinomas and hyper-
vascularized tumors, typically neuroendocrine tumors 
and serous microcystic adenomas of the pancreas. This 
differential diagnosis is of great value because serous mi-
crocystic adenomas do not require surgery in the major-
ity of cases due to their very low malignancy potential. In 
addition, neuroendocrine tumors progress slowly and ad-
juvant treatment is available. Local resection of peripher-
ally located tumors is an optional treatment, or resection 
may be less radical than required according to oncologi-
cal criteria for ductal adenocarcinomas. 
 CEUS techniques have been found to be beneficial in 
the differential diagnosis of chronic pancreatitis and duc-
 Fig. 2. Cystic tumor of the pancreas. The perfusion of the septae 
by CEUS and the vascularized nodules are suggestive of MCN or 
IPMN. 
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tal adenocarcinomas, but results depend on the tools and 
methods employed. For ductal adenocarcinomas, only 
arterial vessels are displayed using power Doppler CEUS. 
Chronic pancreatitis displays both arterial and venous 
vessels equally  [13] . These differences result from the dif-
ferent patterns of histopathological changes. In case of 
chronic inflammation, hemorrhages or thromboses lead 
to scarring and shrinkage of the entire gland and result 
in a fragmented circulation pattern. PDACs, in contrast, 
show a network of capillary vessels surrounding the tu-
mor. Blood flows from the periphery to the core of the 
tumor and arteries are primarily found along the tumor 
margins, so that the contrast agent flows through a ring 
of vessels and only subsequently reaches the central struc-
tures.
 Conventional imaging modalities (unenhanced US, 
CT, MRI, angiography, and positron emission tomogra-
phy) cannot adequately visualize the microvasculariza-
tion specific for the nutrient supply of the tumor. The use 
of CEUS allows a better identification of vascularization 
of solid pancreatic tumors than spiral CT  [19, 48] . Com-
paring CEUS and CT scans with a histological image, a 
significantly better correlation exists between the histo-
logical tumor vascularization described by the CEUS im-
age than that of the CT scan. Tumor vascularity is always 
underestimated in a CT scan  [19, 42] , and significantly 
smaller ‘necrotic’ areas may be visualized by CEUS but 
not in the corresponding CT scan  [51] .
 There may be several reasons for these results: first, the 
kinetics of US and CT contrast agents are different be-
cause US contrast agents remain within the vessels while 
CT contrast agents disperse into the parenchyma. Sec-
ond, in CEUS, vascularity is assessed in a dynamic, real-
time fashion comparing imaging before, after, and dur-
ing the administration of the contrast media, whereas in 
a CT scan the contrast of the lesion is compared with the 
surrounding tissue. Third, CEUS enables repetitive ex-
aminations of the same area with different settings and 
different contrast phases and can thus lead to more dif-
ferentiated information regarding tumor perfusion.
 The differentiation of inflammatory pseudotumors in 
chronic pancreatitis and PDAC has been attempted by 
several groups. Koito et al.  [32] showed that CEUS had a 
higher sensitivity for the confirmation of vascularization 
than CT and digital subtraction angiography. Similar re-
sults were reported by Becker et al. [52] , who demonstrat-
ed a sensitivity of 94% and a specificity of 100% with 
CEUS for the differentiation between PDAC and inflam-
matory pseudotumors. For this differentiation, and with-
out the possibility of simultaneous ‘macroscopic’ imag-
ing, the accuracy of angiography alone was only 50%. 
 Additionally, the resolution of digital subtraction angiog-
raphy is insufficient for the imaging of capillary perfu-
sion  [53, 54] . In CEUS, however, microbubbles in the cap-
illary network can be detected as an increase in contrast, 
which, with appropriate software, can be quantified with 
a sensitivity that is unachievable by visual observation 
alone. The use of quantification software strongly sup-
ports the visual observation of a contrast examination, 
and the software can be used to calculate parameters 
characteristic for a contrast course within lesions and 
normal parenchyma that can help to distinguish pancre-
atic tumors.
 In summary, the successful management and treat-
ment of pancreatic tumors requires highly sensitive and 
specific imaging techniques. CEUS is effective for differ-
entiating solid pancreatic tumors in most cases. Charac-
teristics of a variety of pancreatic lesions are well identi-
fied by contrast-enhanced CT or MRI, but only CEUS is 
able to visualize them in real time. Because CEUS more 
accurately determines pancreatic diseases than baseline 
US, it can directly result in a better diagnostic workup 
and treatment, especially compared to CT or MRI. CEUS 
is safe and cost effective and can better discriminate sol-
id from cystic pancreatic lesions, thereby directing pa-
tients towards a CT if the lesion is solid and towards an 
MRI if the lesion is cystic.
 Nevertheless, histology is still the standard reference 
for the differentiation of pancreatic lesions; however, this 
can still result in false-negative results if the specimens 
obtained are not representative. A transabdominal or en-
dosonographically guided endoscopic biopsy is suggested 
for patients with hypervascular lesions and suspected 
nonfunctional neuroendocrine tumors or serous micro-
cystic adenomas. Biopsy is helpful because the therapeutic 
approach to iso- and hypervascular lesions should be dif-
ferent from that used for the most common hypovascular 
PDACs. In patients with serous cystadenomas, close fol-
low-up might be suggested, whereas nonfunctional neu-
roendocrine tumors will require surgery due to their ma-
lignancy potential. Hypovascular pancreatic lesions in 
patients without a contraindication (e.g. liver metastases 
or peritoneal metastases) should undergo surgery without 
a prior biopsy due to the fact that these imaging findings 
are indicative of PDACs. For cases who are not offered 
surgery due to metastases or other reasons, a biopsy yield-
ing cytology prior to palliative chemotherapy is required. 
Most of the other very rare entities are also hypervascular, 
and a biopsy is mandatory for individualized therapeutic 
strategies, typically resulting in resection.
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